The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
Between 2015 and mid-2025, EU biotech startups attracted €25B in venture capital. In the US, that figure was €219B. To turn things around, Brussels is counting on a legislative package.
Shortly prior to last Christmas the European Commission published a proposal of a European Biotech Act, a strategic initiative aimed at setting up a regulatory framework to strengthen the life sciences sector across the EU. The document has been mostly positively received by the sector leaders as a needed step towards fostering local biotech innovation. Brussels isn’t stopping there. Commission President Ursula von der Leyen pitched EU-Inc, a pan-European company structure meant to solve what many see as the EU’s core startup problem of navigating 27 different bureaucratic regimes. The proposal would let one register in 48 hours, fully online and in English.
Read this Pro article free
Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.
Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.
